INTRODUCTION
Over the past decade, the US FDA's framework for evaluating new drugs has shifted from a predominantly premarket to an increasingly Blifecycle^evaluation process, where benefits and risks are evaluated before and after market approval. 1 In order to resolve remaining uncertainties at the time of premarket approval, such as whether a drug conditionally approved on a surrogate marker improves patient outcomes, many drugs receive postmarketing requirements (PMRs)-FDA-imposed studies that manufacturers must conduct after approval. To avoid delays translating these findings into practice, manufacturers need to complete PMRs on time and FDA should provide reasonable time frames for completion. However, concerns have been raised about manufacturers' lack of adherence to and FDA's lack of enforcement of PMR deadlines. 2 Furthermore, nearly one quarter of PMR results are either not reported on ClinicalTrials.gov or published in the peer-reviewed literature. 3, 4 Therefore, our objective was to characterize the timeliness of PMR studies, comparing FDAestablished timeliness milestones with expected completion times outlined on ClinicalTrials.gov.
METHODS
As previously described, 4 we identified all PMRs from the approval letters in the Drugs@FDA database for new drugs and biologics approved between 2009 and 2012. Approval letters include descriptions of PMRs and identify the regulatory authorities under which they are required (Accelerated Approval (AA), Pediatric Research Equity Act (PREA), or FDA Amendments Act (FDAAA)) ( Table 1) . We limited our sample to clinical PMR studies examining drug safety or efficacy, including new prospective cohort studies, clinical trials, and registries. 4 We collected FDA approval dates for each drug and milestone dates established by FDA for each PMR study, including final protocol submission, trial completion, and final report submission. We searched ClinicalTrials.gov for registration records to identify primary outcomes and the timing of their measurement (e.g., primary outcome ascertainment: change from baseline to day 56 in syndrome scale), as a proxy for expected study duration. Using FDA milestone dates, we determined time from first approval to protocol submission, time from protocol submission to study completion, and time for primary outcome ascertainment. Analyses were performed using R (v.3.2.3). (Table 2) .
Median time from drug approval to protocol submission was longer for clinical trials required under PREA than under FDAAA and AA authorities: 15 (7-37) vs 4 (3-6) and 3 (2-9) months, respectively (Table 2) .
Median PMR study durations set by FDA (protocol submission to study completion) for clinical trials required under PREA, FDAAA, and AA were substantially longer than median time required for primary outcome ascertain-ment: 38 (29-51) vs 3 (1-6), 53 (42-67) vs 12 (3-48), and 72 (56-80) vs 46 (14-60) months, respectively.
DISCUSSION
Across PMR authorities, median times permitted by FDA for manufacturers to submit protocols for PMR clinical trials ranged from 3 to 15 months, while median times allowed for study completion after protocol submission were approximately 2-13-fold longer than that required for primary outcome ascertainment. PREA trials had the longest protocol submission milestones, likely reflecting FDA's policy of deferring studies in children until safety information from other studies is available. 5 AA drugs, which receive provisional approval based on surrogate markers, had the longest PMR trial completion milestones, approximately 2 years longer than the time required for primary outcome ascertainment.
While limited to a relatively small sample of clinical PMR studies with trial information determined from publicly available data, our results suggest that FDA and manufacturers should consider strategies to shorten times allotted for PMR milestones. If FDA currently does not have the capacity to provide detailed oversight during PMR protocol development, additional resources may be necessary to strengthen postmarket evidence generation such as improvements in FDA's data management system. 6 FDA and manufacturers could work to identify PMRs earlier in the approval process, potentially shortening the time from approval to protocol submission and study initiation. Shorter milestones may FDA, Food and Drug Administration; MDR-TB, multidrug-resistant tuberculosis; ABSSSI, acute bacterial skin and structure infection; MRSA, methicillin-resistant Staphylococcus aureus; MI, myocardial infarction; PREA, Pediatric Research Equity Act. Our sample did not contain any clinical trials issued under the Animal Efficacy Rule (AER) (2002) . Under AER, postmarketing requirements may be issued for certain drugs approved without human efficacy studies and field trials when they are not ethical and feasible help ensure more timely resolution of the medical product uncertainties that remain at the time of approval, thereby improving clinical care decision-making and reducing the amount of time that drugs are available without long-term safety and/or efficacy data.
